BSE: 511509 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Vivo Bio Tech Ltd is a average quality company.
The key valuation ratios of Vivo Bio Tech Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vivo Bio Tech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 4.7% | 6% | 12.4% | 15.2% | 9.6% | 14.2% | 19.5% | 9.6% | 11.3% | 10.2% | - |
| Value Creation Index ⓘ | -0.7 | -0.6 | -0.1 | 0.1 | -0.3 | 0.0 | 0.4 | -0.3 | -0.2 | -0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 17.8 | 28.6 | 34.1 | 47 | 55.8 | 55.4 | 51.8 | 51.4 | 51.6 | 44.9 | 43 |
| Sales YoY Gr. | - | 60.7% | 19.4% | 37.7% | 18.8% | -0.9% | -6.5% | -0.8% | 0.5% | -13.1% | - |
| Adj EPS ⓘ | 0.5 | 1 | 2.7 | 3.2 | 1.9 | 3.5 | 4.2 | 1.6 | 1.8 | 1.7 | 1.6 |
| YoY Gr. | - | 96% | 173.5% | 19% | -41.4% | 85.6% | 21.6% | -62.3% | 11.3% | -4% | - |
| BVPS (₹) ⓘ | 9.8 | 10.7 | 13.5 | 17.5 | 21.8 | 25.6 | 30.6 | 32.3 | 34.5 | 36.3 | 36.4 |
| Adj Net Profit ⓘ | 0.5 | 0.9 | 2.5 | 3.1 | 2.3 | 4.5 | 5.7 | 2.3 | 2.6 | 2.5 | 2 |
| Cash Flow from Ops. ⓘ | 2.1 | 8.7 | -5.7 | 11.1 | -0.8 | 7.7 | 14.1 | 16.4 | 14.7 | 15.8 | - |
| Debt/CF from Ops. ⓘ | 2.7 | 1.9 | -4.8 | 2.3 | -27.5 | 2.9 | 2 | 4 | 4.1 | 4.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 10.8% | -4.3% | -4.7% | -13.1% | ||||
| Adj EPS ⓘ | 14.6% | -1.9% | -26.2% | -4% | ||||
| BVPSⓘ | 15.7% | 10.8% | 5.9% | 5.2% | ||||
| Share Price | 8.2% | 3.8% | -15.2% | 13.9% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 5.3 | 9.5 | 22.1 | 19.7 | 9.9 | 14.8 | 15 | 5.1 | 5.3 | 4.8 | 4.5 |
| Op. Profit Mgn % ⓘ | 15.8 | 13 | 22.4 | 23.2 | 17.2 | 22.6 | 34.4 | 31.5 | 42.3 | 47.4 | 46.9 |
| Net Profit Mgn % ⓘ | 2.6 | 3.2 | 7.3 | 6.7 | 4.1 | 8.1 | 11 | 4.4 | 5.1 | 5.7 | 5.6 |
| Debt to Equity ⓘ | 0.6 | 1.7 | 2.2 | 1.5 | 0.8 | 0.7 | 0.7 | 1.4 | 1.2 | 1.3 | 0.6 |
| Working Cap Days ⓘ | 199 | 138 | 155 | 165 | 158 | 170 | 191 | 188 | 204 | 320 | 175 |
| Cash Conv. Cycle ⓘ | -41 | -45 | -11 | 37 | 53 | 81 | 118 | 127 | 131 | 152 | 50 |
No data to display
Return on Equity has declined versus last 3 years average to 4.50%
Sales growth has been subdued in last 3 years -4.66%
Net Profit has been subdued in last 3 years -26.15%
Debt to equity has increased versus last 3 years average to 1.31
Sales growth is not so good in last 4 quarters at -1.10%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1.6 | 1.7 |
| TTM Sales (₹ Cr.) | 43.4 | 44 |
| BVPS (₹.) ⓘ | 36.4 | 36.4 |
| Reserves (₹ Cr.) ⓘ | 40 | 40 |
| P/BV ⓘ | 1.10 | 1.10 |
| PE ⓘ | 24.39 | 23.37 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 30.75 / 56.00 |
| All Time Low / High (₹) | 1.10 / 115.10 |
| Market Cap (₹ Cr.) | 59.6 |
| Equity (₹ Cr.) | 14.9 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17.79 | 28.58 | 34.13 | 47 | 55.83 | 55.35 | 51.78 | 51.39 | 51.62 | 44.88 |
| Operating Expenses ⓘ | 14.98 | 24.88 | 26.50 | 36.12 | 46.32 | 42.88 | 33.97 | 35.30 | 29.80 | 23.63 |
| Manufacturing Costs | 1.91 | 2.55 | 3.12 | 3.10 | 5.07 | 6.89 | 5.87 | 3.77 | 4.56 | 4.24 |
| Material Costs | 3.07 | 8.80 | 8.14 | 9.57 | 11.76 | 8.56 | 7.21 | 11.44 | 6.77 | 3.85 |
| Employee Cost | 2.94 | 4.34 | 5.50 | 7.66 | 9.58 | 10 | 8.57 | 9.42 | 13.15 | 10.13 |
| Other Costs ⓘ | 7.07 | 9.18 | 9.74 | 15.80 | 19.91 | 17.43 | 12.32 | 10.67 | 5.32 | 5.41 |
| Operating Profit ⓘ | 2.81 | 3.71 | 7.63 | 10.88 | 9.51 | 12.47 | 17.81 | 16.09 | 21.82 | 21.25 |
| Operating Profit Margin (%) | 15.8% | 13.0% | 22.4% | 23.2% | 17.0% | 22.5% | 34.4% | 31.3% | 42.3% | 47.4% |
| Other Income ⓘ | 0.95 | 0.89 | 0.40 | 0.13 | 0.01 | 0.05 | 0.08 | 0.09 | 0.04 | 0.04 |
| Interest ⓘ | 0.51 | 0.47 | 1.29 | 2.37 | 2.64 | 3.10 | 3.67 | 4.27 | 7.99 | 7.95 |
| Depreciation ⓘ | 3.05 | 3.35 | 3.90 | 4.64 | 5.06 | 5.17 | 5.59 | 7.44 | 9.27 | 9.29 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0.19 | 0.78 | 2.84 | 4.01 | 1.83 | 4.26 | 8.62 | 4.47 | 4.61 | 4.05 |
| Tax ⓘ | -0.27 | -0.13 | 0.33 | 0.88 | -0.42 | -0.19 | 2.94 | 2.27 | 1.97 | 1.53 |
| Profit After Tax | 0.46 | 0.91 | 2.50 | 3.12 | 2.25 | 4.44 | 5.68 | 2.20 | 2.63 | 2.52 |
| PAT Margin (%) | 2.6% | 3.2% | 7.3% | 6.6% | 4.0% | 8.0% | 11.0% | 4.3% | 5.1% | 5.6% |
| Adjusted EPS (₹) | 0.5 | 1.0 | 2.7 | 3.2 | 1.8 | 3.5 | 4.2 | 1.5 | 1.8 | 1.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 9.17 | 10.08 | 12.60 | 17.23 | 26.98 | 33.04 | 41.12 | 46.46 | 51.87 | 54.40 |
| Share Capital ⓘ | 9.35 | 9.35 | 9.35 | 9.85 | 12.35 | 12.89 | 13.42 | 14.26 | 14.90 | 14.90 |
| Reserves ⓘ | -0.18 | 0.73 | 3.25 | 7.38 | 14.63 | 20.15 | 27.70 | 32.19 | 36.97 | 39.49 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 5.69 | 16.91 | 27.06 | 25.11 | 21.67 | 22.09 | 24.35 | 58.80 | 52.45 | 62.24 |
| Long Term Debt | 2.66 | 14.11 | 20.93 | 13.90 | 8.90 | 7.41 | 12.42 | 47.88 | 40.87 | 39.56 |
| Short Term Debt | 3.03 | 2.81 | 6.12 | 11.21 | 12.77 | 14.67 | 11.92 | 10.92 | 11.59 | 22.68 |
| Trade Payables | 6.85 | 8.75 | 5.40 | 7.98 | 3.87 | 3.91 | 1.39 | 2.32 | 0.94 | 1.06 |
| Others Liabilities ⓘ | 19.71 | 9.93 | 6.08 | 9.20 | 2.56 | 0.84 | 10.46 | 12.73 | 15.54 | 17.10 |
| Total Liabilities ⓘ | 41.43 | 45.67 | 51.14 | 59.53 | 55.08 | 59.87 | 77.31 | 120.30 | 120.81 | 134.80 |
Fixed Assets | ||||||||||
| Gross Block | 27.82 | 34.95 | 43.88 | 47.61 | 55.02 | 62 | 84.65 | 135.16 | 138.12 | 138.70 |
| Accumulated Depreciation | 8.25 | 11.60 | 15.51 | 20.14 | 25.20 | 30.37 | 35.97 | 43.35 | 52.61 | 61.69 |
| Net Fixed Assetsⓘ | 19.57 | 23.35 | 28.37 | 27.47 | 29.82 | 31.63 | 48.69 | 91.81 | 85.51 | 77.01 |
| CWIP ⓘ | 0.07 | 0.04 | 2.96 | 3.94 | 0.07 | 0.15 | 0.32 | 0.87 | 1.90 | 9.21 |
| Investmentsⓘ | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Inventories | 4.69 | 4.08 | 4.56 | 7.59 | 8.24 | 10.58 | 13.28 | 9.81 | 7.97 | 8.77 |
| Trade Receivables | 4.31 | 3.82 | 7.67 | 11.78 | 8.41 | 10.48 | 7.29 | 12.02 | 12.38 | 11.37 |
| Cash Equivalents | 10.56 | 11.85 | 1.18 | 4.15 | 0.53 | 0.99 | 1.10 | 1.47 | 0.99 | 1.32 |
| Others Assetsⓘ | 2.22 | 2.50 | 6.36 | 4.58 | 7.99 | 6 | 6.59 | 4.28 | 12.01 | 27.08 |
| Total Assets ⓘ | 41.43 | 45.67 | 51.14 | 59.53 | 55.08 | 59.87 | 77.31 | 120.30 | 120.81 | 134.80 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 2.13 | 8.73 | -5.65 | 11.11 | -0.79 | 7.72 | 14.10 | 16.43 | 14.73 | 15.83 |
| PBT ⓘ | 0.19 | 0.78 | 2.85 | 4.01 | 1.83 | 4.26 | 8.62 | 4.47 | 4.61 | 4.05 |
| Adjustment ⓘ | 3.56 | 3.82 | 5.19 | 7.02 | 7.70 | 8.27 | 9.12 | 11.43 | 16.92 | 17.07 |
| Changes in Working Capital ⓘ | -1.08 | 4.47 | -12.07 | 3.34 | -8.1 | -1.9 | 2.82 | 3.98 | -3.46 | -2.24 |
| Tax Paid ⓘ | -0.04 | 0.13 | -0.33 | -0.88 | 0.42 | 0.19 | -2.94 | -2.27 | -1.97 | -1.53 |
| Cash Flow From Investing Activity ⓘ | -1.92 | -7.12 | -11.84 | -4.72 | -3.53 | -7.08 | -22.82 | -51.11 | -4 | -7.95 |
| Capex | -2.03 | -7.11 | -11.84 | -4.72 | -3.53 | -7.07 | -22.82 | -51.11 | -4 | -7.95 |
| Net Investments | 0.12 | -0.01 | 0 | 0 | 0 | -0.01 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | -0.89 | -0.32 | 6.83 | -3.43 | 0.70 | -0.18 | 8.83 | 35.04 | -11.20 | -7.56 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 1.50 | 5.70 | 1.31 | 3.82 | 2.40 | 2.10 | 0 |
| Net Proceeds from Borrowing ⓘ | -0.89 | -0.32 | 6.83 | -4.93 | -5 | -1.49 | 5.01 | 35.45 | -7.01 | -1.30 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.81 | -6.28 | -6.25 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | -0.68 | 1.29 | -10.67 | 2.96 | -3.62 | 0.46 | 0.11 | 0.37 | -0.47 | 0.32 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 5.25 | 9.48 | 22.14 | 20.98 | 10.21 | 14.85 | 15.35 | 5.06 | 5.41 | 4.78 |
| ROCE (%) | 4.72 | 5.96 | 12.39 | 15.17 | 9.58 | 14.15 | 19.47 | 9.55 | 11.26 | 10.15 |
| Asset Turnover Ratio | 0.44 | 0.66 | 0.71 | 0.85 | 0.97 | 0.96 | 0.75 | 0.52 | 0.43 | 0.35 |
| PAT to CFO Conversion(x) | 4.63 | 9.59 | -2.26 | 3.56 | -0.35 | 1.74 | 2.48 | 7.47 | 5.6 | 6.28 | Working Capital Days |
| Receivable Days | 88 | 52 | 61 | 75 | 66 | 62 | 63 | 69 | 86 | 97 |
| Inventory Days | 51 | 56 | 46 | 47 | 52 | 62 | 84 | 82 | 63 | 68 |
| Payable Days | 915 | 324 | 317 | 255 | 184 | 166 | 134 | 59 | 88 | 95 |
Vivo Bio Tech was incorporated on February 12, 1987 as Golden Growth Fund, Hyderabad-based Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities. The company was converted into a public limited company from Jun. 19, 1992. VBTL provides services ranging from insilico design, wet lab contract research, preclinical research and clinical studies spanning the entire drug discovery value chain.
It is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of custom research, In-vitro and In-vivo toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Our experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. Tailored and dedicated to our clients, we distinguish your development plan is as superlative as the products you bring to our testing facilities.
The Custom Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Our scientists will team up with you to develop solution for the most difficult to deal products including purification of untagged & poorly expressed proteins.
In-vitro Services offers solutions for pharmacologic, toxicological & bioanalytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by our scientists.
Vivo Bio Tech has obtained permission from the Govt. of India for developing Biotech Sector Specific 'Special Economic Zone' at its site (39 acres) in Pregnapur, Gajwel Mandal, Medak District, Andhra Pradesh.The Vivo Bio Tech SEZ is located adjacent to Karimnagar highway road (approx 16 km from ICICI Knowledge Park and SP Biotech Park). The site is approximately 53km from Secunderabad Railway Station and around 90km from the new airport (Shamshabad).
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
